stage I multiple myeloma
Showing 1 - 25 of >10,000
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma Trial in Canada, United States (drug, procedure,
Active, not recruiting
- Stage I Multiple Myeloma
- +2 more
- dexamethasone
- +4 more
-
Chicago, Illinois
- +4 more
Sep 3, 2022
Multiple Myeloma and Plasma Cell Tumor Trial in Buffalo (dexamethasone, doxorubicin HCl, thalidomide)
Completed
- Multiple Myeloma and Plasma Cell Neoplasm
- dexamethasone
- +3 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Sep 30, 2022
Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma Stage II Trial in London (Rivaroxaban, ASA)
Recruiting
- Multiple Myeloma in Relapse
- +5 more
-
London, Ontario, CanadaLondon Health Sciences Centre
Oct 3, 2022
ISS Stage I Plasma Cell Myeloma, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma Trial in Atlanta
Active, not recruiting
- ISS Stage I Plasma Cell Myeloma
- +4 more
- Pembrolizumab
- Radiation Therapy
-
Atlanta, GeorgiaEmory University/Winship Cancer Institute
Mar 2, 2022
Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma Trial in Duarte (radiation, drug, procedure,
Completed
- Refractory Multiple Myeloma
- +4 more
- total marrow irradiation
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 25, 2021
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia Trial in Duarte (drug,
Active, not recruiting
- Autologous Hematopoietic Stem Cell Transplant Recipient
- +4 more
- bortezomib
- +7 more
-
Duarte, CaliforniaCity of Hope
Mar 17, 2022
Multiple Myeloma and Plasma Cell Tumor, Neurotoxicity Trial in Duarte (drug, genetic, other, procedure)
Completed
- Multiple Myeloma and Plasma Cell Neoplasm
- Neurotoxicity
- bortezomib
- +9 more
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 17, 2021
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in
Active, not recruiting
- Accelerated Phase Chronic Myelogenous Leukemia
- +125 more
- tetanus-CMV fusion peptide vaccine
- laboratory biomarker analysis
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 28, 2022
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma
Completed
- Adult Grade III Lymphomatoid Granulomatosis
- +88 more
- bortezomib
- +2 more
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Apr 14, 2021
Collecting Blood Samples From and Without Cancer to Evaluate
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +61 more
- Questionnaire Administration
- Biospecimen Collection
- (no location specified)
Apr 12, 2022
Multiple Myeloma, Refractory Multiple Myeloma Trial (procedure, drug, radiation)
Withdrawn
- Multiple Myeloma
- Refractory Multiple Myeloma
- nonmyeloablative allogeneic hematopoietic stem cell transplantation
- +7 more
- (no location specified)
Jan 4, 2023
Multiple Myeloma Trial in Wollongong (IBI3003)
Not yet recruiting
- Multiple Myeloma
-
Wollongong, New South Wales, AustraliaWollongong Private Hospital
Oct 18, 2023
Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma Trial in Changsha (BEBT-908 for
Completed
- Relapsed or Refractory Non-Hodgkin's Lymphoma
- Relapsed or Refractory Multiple Myeloma
- BEBT-908 for injection
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Oct 9, 2023
Newly Diagnosed Multiple Myeloma Trial in Germany (Isatuximab, Lenalidomide, Bortezomib)
Not yet recruiting
- Newly Diagnosed Multiple Myeloma
- Isatuximab
- +4 more
-
Hamburg, Germany
- +3 more
Dec 16, 2022
Multiple Myeloma Trial (CM313 injection)
Not yet recruiting
- Multiple Myeloma
- CM313 injection
- (no location specified)
Nov 6, 2023
Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma Trial in Zhengzhou, Shengyang, Hangzhou (HRS-3738)
Recruiting
- Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
-
Zhengzhou, Henan, China
- +2 more
Jul 27, 2022
Multiple Myeloma Trial in Korea, Republic of, Poland, Spain (Cevostamab, Lenalidomide, Tocilizumab)
Not yet recruiting
- Multiple Myeloma
- Cevostamab
- +2 more
-
Seoul, Korea, Republic of
- +4 more
Jan 11, 2023
Multiple Myeloma, Multiple Myeloma in Relapse Trial (Belantamab mafodotin, Venetoclax)
Not yet recruiting
- Multiple Myeloma
- Multiple Myeloma in Relapse
- Belantamab mafodotin, Venetoclax
- (no location specified)
May 10, 2023
Multiple Myeloma Trial in Houston (Belumosudil mesylate)
Not yet recruiting
- Multiple Myeloma
- Belumosudil mesylate
-
Houston, TexasM D Anderson Cancer Center
Oct 31, 2023
Multiple Myeloma Trial in Saint Louis (drug, device, procedure)
Recruiting
- Multiple Myeloma
- 64Cu-LLP2A
- +7 more
-
Saint Louis, MissouriWashington University School of Medicine
Jul 27, 2022
Multiple Myeloma Trial in Ann Arbor (Iodine I 131 Tositumomab)
Active, not recruiting
- Multiple Myeloma
- Iodine I 131 Tositumomab
-
Ann Arbor, MichiganUniversity of Michigan
Mar 16, 2022
Multiple Myeloma Trial (BCMA-TGFß CAR-T cells (0.75 x10^6 cells/kg), BCMA-TGFß CAR-T cells (1 x 10^6 cells/kg), BCMA-TGFß CAR-T
Not yet recruiting
- Multiple Myeloma
- BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)
- +3 more
- (no location specified)
Jul 28, 2023
Multiple Myeloma, Multiple Myeloma in Relapse Trial in Boston (Ixazomib, Pomalidomide, Dexamethasone)
Recruiting
- Multiple Myeloma
- Multiple Myeloma in Relapse
- Ixazomib
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Apr 13, 2022